肿瘤细胞治疗研究
ALL SOURCES
Metabolic Reprogramming of NSUN2-Mediated m(5)C Modification Promotes the Progression of Hepatocellular Carcinoma by Restricting Natural Killer Cell-M
这些发现提示，NSUN2 可能是 m5C RNA 甲基化与免疫抑制之间的关键枢纽，为 HCC 的联合免疫治疗提供了治疗依据。
A novel combination therapy for effective treatment of cancer by designed anti-immunosuppressive nanoregulator and radiofrequency ablation.
这些数据为有效治疗HCC及可能其他类型的癌症开辟了一条新的治疗途径。
A tumor-on-a-chip model reveals and targets reciprocal macrophage-NK cell crosstalk to advance immunotherapy screening.
有效的癌症免疫治疗受到肿瘤微环境中免疫抑制性串扰的阻碍。
CPNE1 promotes stemness and confers resistance to GPC3 CAR-T cell therapy in hepatocellular carcinoma via the STAT3-TGF-β signaling pathway.
这些发现表明CPNE1是HCC进展和免疫抑制的关键调控因子，突显了CPNE1-STAT3-TGF-轴作为HCC中有前景的治疗靶点。
Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in patients with Advanced Hepatocellular Carcinoma.
CT0180在经多线治疗的HCC中显示出初步可控的安全性特征和临床活性，支持进一步开展临床评价。
Spatial architecture of tertiary lymphoid structures represents an independent prognostic dimension in hepatocellular carcinoma.
本研究确立了TLS空间背景作为其在HCC免疫中双重角色的决定因素，大规模证明了基于TLS位置的对立预后作用。SpatialDecoder流程和四表型框架将TLS评估从二元指标转变为用于术后风险分层的空间信息方法。
ASB2 inhibits lipid accumulation to promote ILC1 homeostatic fitness and anti-tumor immunity in the mouse liver.
1型固有淋巴细胞（ILC1）在成人肝脏中含量丰富，对免疫监视和免疫调节至关重要，但其维持和功能的调控机制仍未得到充分研究。
GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma.
这些结果表明C-CAR031在重度经治的晚期HCC患者中具有可控的安全性特征和令人鼓舞的抗肿瘤活性。
Self-Cooperative RNA Vaccine Mitigates Dendritic Cell-Mediated Acquired Immune Resistance to Potentiate Cell Therapy for Solid Tumors.
传统 mRNA 癌症疫苗旨在最大化抗原效力，但往往忽视了疫苗接种诱导的免疫抵抗。
Targeting cholesterol esterification sensitizes liver cancer to CD8(+) T cell attack by impairing metabolic and redox resilience.
肿瘤切除和肝移植后的复发仍是肝细胞癌（HCC）面临的主要临床挑战。
MEMBER ACCOUNT
登录成功会直接打开下一页。
